Form 4: Novavax Director John W. Shiver Reports Stock Option and Restricted Stock Unit Grants

Director John W. Shiver reports the acquisition of stock options and restricted stock units in Novavax, Inc.

Summary

• On March 10, 2025, John W. Shiver, a director of Novavax, Inc., was granted stock options for 35,770 shares and 23,840 restricted stock units (RSUs).
• The stock options have an exercise price of $8.20 and vest in three equal installments on the anniversaries of the grant date, contingent upon continued service on the Board of Directors.
• Each RSU represents the right to receive one share of Novavax common stock and also vests in three equal installments on the anniversaries of the grant date, subject to continued service on the Board of Directors.
• Following these transactions, Shiver directly owns 35,770 stock options and 23,840 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a routine disclosure of stock option and RSU grants. It's a positive for the individual but doesn't necessarily indicate a significant shift in the company's prospects.

Positives

• The grants of stock options and RSUs align the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, particularly in the biotech industry.
• Vesting schedules of three years are also typical to ensure long-term alignment with company performance.
• Comparable companies like Moderna or BioNTech also utilize similar equity-based compensation plans for their directors and executives.

Stakeholder Impact

• Shareholders may view the grants as a positive incentive for the director to contribute to the company's long-term success.
• Employees may see this as a standard practice for rewarding key personnel.

Key Dates